Chemerin Regulates Crosstalk between Adipocytes and Vascular Cells Through Nox

Hypertension

Volumn 66, Issue 3, 2015, Pages 657-666

  Neves, Karla Bianca ^a,b   Nguyen Dinh Cat, Aurelie ^a   Lopes, Rheure Alves Moreira ^a,b   Rios, Francisco Jose ^a   Anagnostopoulou, Aikaterini ^a   Lobato, Nubia Souza ^c   De Oliveira, Ana Maria ^b   Tostes, Rita C ^b   Montezano, Augusto C ^a   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

adipokines; diabetes mellitus; obesity; reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; BROXURIDINE; CHEMERIN; CYCLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; STRESS ACTIVATED PROTEIN KINASE; VASCULAR CELL ADHESION MOLECULE 1; CASPASE 3; CHEMERIN PROTEIN, HUMAN; CHEMOKINE; SIGNAL PEPTIDE;

ADIPOCYTE; ANIMAL CELL; APOPTOSIS; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL GROWTH; CELL PROLIFERATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MONOCYTE; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUNEL ASSAY; VASCULAR SMOOTH MUSCLE CELL; CELL COMMUNICATION; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ADIPOCYTES; APOPTOSIS; CASPASE 3; CELL COMMUNICATION; CHEMOKINES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES;

EID: 84939230154     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05616     Document Type: Article

References (51)

1. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ. N Engl J Med. 2001;345:1345-1346. doi: 10.1056/NEJM200111013451814.
2. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res. 2005;126:121-129. doi: 10.1016/j.jss.2004.12.023.
3. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB. [The adipose tissue as a regulatory center of the metabolism]. Arq Bras Endocrinol Metabol. 2006;50:216-229. doi: /S0004-27302006000200008.
4. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011;34:307-310.
5. Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev. 2013;14:245-262. doi: 10.1111/obr.12009.
6. Matsuzawa Y. White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab. 2005;19:637-647. doi: 10.1016/j. beem.2005.07.001.
7. Watts SW, Dorrance AM, Penfold ME, Rourke JL, Sinal CJ, Seitz B, Sullivan TJ, Charvat TT, Thompson JM, Burnett R, Fink GD. Chemerin connects fat to arterial contraction. Arterioscler Thromb Vasc Biol. 2013;33:1320-1328. doi: 10.1161/ATVBAHA.113.301476.
8. Matsuzawa Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2006;3:35-42. doi: 10.1038/ncpcardio0380.
9. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282:28175-28188. doi: 10.1074/jbc.M700793200.
10. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687-4694. doi: 10.1210/en.2007-0175.
11. Issa ME, Muruganandan S, Ernst MC, Parlee SD, Zabel BA, Butcher EC, Sinal CJ, Goralski KB. Chemokine-like receptor 1 regulates skeletal muscle cell myogenesis. Am J Physiol Cell Physiol. 2012;302:C1621-C1631. doi: 10.1152/ajpcell.00187.2011.
12. Takahashi M, Okimura Y, Iguchi G, et al. Chemerin regulates cell function in mice. Sci Rep. 2011;1:123. doi: 10.1038/srep00123.
13. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D. Specific recruitment of antigenpresenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977-985. doi: 10.1084/jem.20030382.
14. Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21:660-667. doi: 10.1016/j. tem.2010.08.001.
15. Wittamer V, Grégoire F, Robberecht P, Vassart G, Communi D, Parmentier M. The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem. 2004;279:9956-9962. doi: 10.1074/jbc.M313016200.
16. Zabel BA, Nakae S, Zúñiga L, Kim JY, Ohyama T, Alt C, Pan J, Suto H, Soler D, Allen SJ, Handel TM, Song CH, Galli SJ, Butcher EC. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med. 2008;205:2207-2220. doi: 10.1084/jem.20080300.
17. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Sasaki S. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362:1013-1018. doi: 10.1016/j. bbrc.2007.08.104.
18. Ernst MC, Issa M, Goralski KB, Sinal CJ. Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology. 2010;151:1998-2007. doi: 10.1210/en.2009-1098.
19. Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology. 2010;151:2590-2602. doi: 10.1210/en.2009-0794.
20. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab. 2013;98:E514-E517. doi: 10.1210/jc.2012-3673.
21. Ernst MC, Haidl ID, Zúñiga LA, Dranse HJ, Rourke JL, Zabel BA, Butcher EC, Sinal CJ. Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology. 2012;153:672-682. doi: 10.1210/en.2011-1490.
22. Rouger L, Denis GR, Luangsay S, Parmentier M. ChemR23 knockout mice display mild obesity but no deficit in adipocyte differentiation. J Endocrinol. 2013;219:279-289. doi: 10.1530/JOE-13-0106.
23. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010;72:342-348. doi: 10.1111/j.1365-2265.2009.03664.x.
24. Yamamoto T, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P, Axelsson J. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant. 2010;25:4017-4023. doi: 10.1093/ndt/gfq329.
25. Adrych K, Stojek M, Smoczynski M, Sledzinski T, Sylwia SW, Swierczynski J. Increased serum chemerin concentration in patients with chronic pancreatitis. Dig Liver Dis. 2012;44:393-397. doi: 10.1016/j. dld.2011.06.020.
26. Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Szczygiel B, Berdowska A, Mazur W, Wozniak-Grygiel E, Kryczka W. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat. 2010;17:661-667. doi: 10.1111/j.1365-2893.2009.01224.x.
27. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol. 2011;46:91-97. doi: 10.3109/00365521.2010.516452.
28. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009;161:339-344. doi: 10.1530/EJE-09-0380.
29. Yamawaki H, Kameshima S, Usui T, Okada M, Hara Y. A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem Biophys Res Commun. 2012;423:152-157. doi: 10.1016/j.bbrc.2012.05.103.
30. Mariani F, Roncucci L. Chemerin/chemR23 axis in inflammation onset and resolution. Inflamm Res. 2015;64:85-95. doi: 10.1007/ s00011-014-0792-7.
31. Neves KB, Lobato NS, Lopes RA, Filgueira FP, Zanotto CZ, Oliveira AM, Tostes RC. Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity Clin Sci (Lond). 2014;127:111-122. doi: 10.1042/CS20130286.
32. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Correa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-1078. doi: 10.1161/ HYPERTENSIONAHA.111.190223.
33. Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M. Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation. Atherosclerosis. 2014;235:256-262. doi: 10.1016/j. atherosclerosis.2014.05.912.
34. Meric M, Soylu K, Avci B, Yuksel S, Gulel O, Yenercag M, Coksevim M, Uzun A. Evaluation of plasma chemerin levels in patients with non-dipper blood pressure patterns. Med Sci Monit. 2014;20:698-705. doi: 10.12659/ MSM.890784.
35. Bir SC, Kolluru GK, Fang K, Kevil CG. Redox balance dynamically regulates vascular growth and remodeling. Semin Cell Dev Biol. 2012;23:745-757. doi: 10.1016/j.semcdb.2012.05.003.
36. Tabet F, Schiffrin EL, Callera GE, He Y, Yao G, Ostman A, Kappert K, Tonks NK, Touyz RM. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res. 2008;103:149-158. doi: 10.1161/CIRCRESAHA.108.178608.
37. Al Ghouleh I, Khoo NK, Knaus UG, et al. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med. 2011;51:1271-1288. doi: 10.1016/j. freeradbiomed.2011.06.011.
38. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol. 2003;30:860-866.
39. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327-332.
40. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92:1023-1033. doi: 10.1210/jc.2006-1055.
41. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918. doi: 10.1161/CIRCULATIONAHA.106.171016.
42. Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010;185:3728-3739. doi: 10.4049/ jimmunol.0902154.
43. Van Heerebeek L, Meischl C, Stooker W, Meijer CJ, Niessen HW, Roos D. NADPH oxidase(s): new source(s) of reactive oxygen species in the vascular system? J Clin Pathol. 2002;55:561-568.
44. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245-313. doi: 10.1152/physrev.00044.2005.
45. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, Arner P, Eckel J. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes. 2009;58:2731-2740. doi: 10.2337/db09-0277.
46. Shen W, Tian C, Chen H, Yang Y, Zhu D, Gao P, Liu J. Oxidative stress mediates chemerin-induced autophagy in endothelial cells. Free Radic Biol Med. 2013;55:73-82. doi: 10.1016/j. freeradbiomed.2012.11.011.
47. Carlino C, Trotta E, Stabile H, et al. Chemerin regulates NK cell accumulation and endothelial cell morphogenesis in the decidua during early pregnancy. J Clin Endocrinol Metab. 2012;97:3603-3612. doi: 10.1210/ jc.2012-1102.
48. Lobato NS, Neves KB, Filgueira FP, Fortes ZB, Carvalho MH, Webb RC, Oliveira AM, Tostes RC. The adipokine chemerin augments vascular reactivity to contractile stimuli via activation of the MEK-ERK1/2 pathway. Life Sci. 2012;91:600-606. doi: 10.1016/j.lfs.2012.04.013.
49. Yang H, Li F, Kong X, Yuan X, Wang W, Huang R, Li T, Geng M, Wu G, Yin Y. Chemerin regulates proliferation and differentiation of myoblast cells via ERK1/2 and mTOR signaling pathways. Cytokine. 2012;60:646-652. doi: 10.1016/j.cyto.2012.07.033.
50. Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun. 2010;391:1762-1768. doi: 10.1016/j.bbrc.2009.12.150.
51. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valentí V, Silva C, Gil MJ, Salvador J, Frühbeck G. Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor- stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis. 2013;9:306-314. doi: 10.1016/j.soard.2011.11.001.